Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Meets EU Conditions for Varian Purchase

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today said that the European Commission has informed the firm that it has met the conditions set forth in January for Agilent's proposed acquisition of Varian.

Agilent agreed in July 2009 to acquire Varian for around $1.5 billion. But regulatory officials in the EU and US had competition concerns, and in January the European Commission told the firm that Varian would have to divest some product lines.

In early March, Agilent reached an agreement with Bruker to acquire from Varian its global inductively coupled plasma mass spectrometry instruments business; its global laboratory gas chromatography instruments business; and its global gas chromatography triple-quadrupole mass spectrometry instruments business.

Agilent said in a filing with the US Securities and Exchange Commission today that the merger still remains subject to approval by the US Federal Trade Commission and the satisfaction of certain closing conditions.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.